Raredr

Emerging Therapies for Duchenne Muscular Dystrophy

Jean Mah, MD
Published Online: Friday, Nov 04, 2016



Jean L Mah, MD,  Associate Professor of Pediatric Neurology at Alberta Children's Hospital talks about the history, pathogenesis, treatment, and standard of care for boys with Duchenne muscular dystrophy. This symposium was filmed at the Child Neurology Society annual meeting in Vancouver, Canada on October 28, 2016.
 
Some of the therapies/targets discussed by Dr Mah include eteplirsen, SRP-053, NS-065, SRP-4045, DS-514b, ataluren, follistatin, AAV microdystrophin, GALGT2, myoblast transplant, cardiac stell cells, iPS stem cells, ezutrmid, domoagrozumab, BMS-986089, FG-3019, CAT-1004, givinostat, vamorolone, rimiporide, ARM210, nebivolol, spriromolactone, eplerenone, Ramipril, carvedilol, and idebenone. 
 
For more information about some of the clinical trials and therapies discussed by Dr Mah, visit jettfoundation.org.

Rare Disease Report would like to thank Dr Mah and the Jett Foundation for their support in allowing us to film this symposium and to share it with the rare disease community.

Latest Articles
Last month, Steve placed first in his division. Two days later, he was busy training for the next contest (May 2017).
Today, the American Health Care Act (aka TrumpCare) is being voted in Congress. The bill needs 215 votes to be approved. It is likely that no Democrats support it, meaning that only 21 Republicans can vote against the bill and it can still get approved.
PANDAS, or pediatric acute-onset neuropsychiatric syndrome, links the sudden onset of OCD or tic-like symptoms to streptococcal-A (GABHS). Could this mysterious affliction be a rare disease or not a disease at all?
To celebrate Rare Disease Day on February 28, 2017, Amicus Therapeutics hosted CabaRare at their Cranbury, N.J. headquarters in which four young people with rare diseases shared their musical talents
$vacMongoViewPlus$ $vAR$